HK Stock Market Move | CSTONE PHARMA-B(02616) rose over 6% again, up over 25% within the month. The British officially approved the phase III clinical trial of sugrelma monoclonal antibodies for NSCLC.

CSTONE PHARMA-B (02616) rose more than 6%, with a cumulative increase of over 25% within the month. As of the time of writing, it rose by 5.03% to 6.68 Hong Kong dollars with a trading volume of 1.02 billion Hong Kong dollars. On the news front, on February 23, CStone Pharma announced that its PD-L1 antibody, sugleimab, has been officially approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication for stage III non-small cell lung cancer (NSCLC). This approval follows the EC approval in July 2024, marking another key breakthrough in the European core market. In addition, CStone Pharma's core asset CS2009, used for the II phase clinical trial of advanced solid tumors, has recently received FDA approval for its IND application. The IND application for CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) for the II phase clinical trial of a new drug for advanced solid tumors has been approved by the U.S. Food and Drug Administration (FDA), signifying a significant advancement in the global development of this innovative immunotherapy.